Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Prabakaran, Thaneas ^a   Nielsen, Rikke ^a   Satchell, Simon C ^b   Mathieson, Peter W ^b   Feldt Rasmussen, Ulla ^c   Sørensen, Søren S ^c   Christensen, Erik I ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; IODINE 125; POLYCLONAL ANTIBODY; SOMATOMEDIN B RECEPTOR; SORTILIN;

ADULT; ARTICLE; BINDING AFFINITY; CASE REPORT; CELL CULTURE; CELL LABELING; CELL TRANSPORT; ENDOCYTOSIS; ENDOTHELIUM CELL; ENZYME LOCALIZATION; ENZYME REPLACEMENT; FABRY DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; INTERNALIZATION; KIDNEY BIOPSY; KIDNEY BLOOD VESSEL; KIDNEY ENDOTHELIUM CELL; LYSOSOME; MALE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RECEPTOR BINDING; VASCULAR ENDOTHELIUM;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADULT; ALPHA-GALACTOSIDASE; ANTIGENS, CD31; CELLS, CULTURED; ENDOCYTOSIS; ENDOTHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IODINE RADIOISOTOPES; KIDNEY; MALE; PROTEIN BINDING; RECEPTOR, IGF TYPE 2; RECOMBINANT PROTEINS;

EID: 84863104164     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039975     Document Type: Article

References (45)

1. Desnick RJ, Ioannou YA, Eng CM, (2006) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR BA, Sly WS, Valle D (eds), editors. pp. 3733-3774 editor. The Metabolic and Molecular Bases of Inherited Disease. 8 ed. New York, NY.: McGraw-Hill.
2. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, et al. (1967) Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276: 1163-1167.
3. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, et al. (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81: 122-138.
4. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, et al. (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61: 249-255.
5. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, et al. (2000) Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 69: 2337-2339.
6. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, et al. (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97: 365-370.
7. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, et al. (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933-1946.
8. Tondel C, Bostad L, Hirth A, Svarstad E, (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51: 767-776.
9. Alroy J, Sabnis S, Kopp JB, (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13: S134-138.
10. Fervenza FC, Torra R, Warnock DG, (2008) Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics 2: 823-843.
11. Dahms NM, Lobel P, Kornfeld S, (1989) Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem 264: 12115-12118.
12. Sando GN, Neufeld EF, (1977) Recognition and receptor-mediated uptake of a lysosomal enzyme, alpha-l-iduronidase, by cultured human fibroblasts. Cell 12: 619-627.
13. Kaplan A, Achord DT, Sly WS, (1977) Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts. Proc Natl Acad Sci U S A 74: 2026-2030.
14. Christensen EI, Zhou Q, Sorensen SS, Rasmussen AK, Jacobsen C, et al. (2007) Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol 18: 698-706.
15. Prabakaran T, Nielsen R, Larsen JV, Sørensen SS, Rasmussen UF, et al. (2011) Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease. PLoS ONE 6: e25065.
16. Munck Petersen C, Nielsen MS, Jacobsen C, Tauris J, Jacobsen L, et al. (1999) Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. EMBO J 18: 595-604.
17. Vinge L, Lees GE, Nielsen R, Kashtan CE, Bahr A, et al. (2010) The effect of progressive glomerular disease on megalin-mediated endocytosis in the kidney. nephrol Dial Transplant 25: 2458-2467.
18. Satchell SC, Tasman CH, Singh A, Ni L, Geelen J, et al. (2006) Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int 69: 1633-1640.
19. Greenwood FC, Hunter WM, Glover JS, (1963) The Preparation of I-131-Labelled Human Growth Hormone of High Specific Radioactivity. Biochem J 89: 114-123.
20. Tauris J, Ellgaard L, Jacobsen C, Nielsen MS, Madsen P, et al. (1998) The carboxy-terminal domain of the receptor-associated protein binds to the Vps10p domain of sortilin. FEBS Lett 429: 27-30.
21. Ghosh P, Dahms NM, Kornfeld S, (2003) Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4: 202-212.
22. Mitsias P, Levine SR, (1996) Cerebrovascular complications of Fabry's disease. Ann Neurol 40: 8-17.
23. Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, et al. (2003) Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 14: 298-302.
24. Moore DF, Kaneski CR, Askari H, Schiffmann R, (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257: 258-263.
25. Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, et al. (2001) Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32: 1559-1562.
26. Heare T, Alp NJ, Priestman DA, Kulkarni AB, Qasba P, et al. (2007) Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. J Inherit Metab Dis 30: 79-87.
27. Moore DF, Ye F, Brennan ML, Gupta S, Barshop BA, et al. (2004) Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 20: 674-683.
28. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, et al. (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47: 229-233.
29. Gelderman MP, Schiffmann R, Simak J, (2007) Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy. Arterioscler Thromb Vasc Biol 27: e138-139.
30. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, et al. (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104: 1506-1512.
31. Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, et al. (2005) Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111: 629-632.
32. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, et al. (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95: 163-168.
33. Goligorsky MS, Chen J, Brodsky S, (2001) Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 37: 744-748.
34. Shen JS, Meng XL, Schiffmann R, Brady RO, Kaneski CR, (2007) Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol Genet Metab 92: 137-144.
35. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9-16.
36. Petersen CM, Nielsen MS, Nykjaer A, Jacobsen L, Tommerup N, et al. (1997) Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J Biol Chem 272: 3599-3605.
37. Willnow TE, Petersen CM, Nykjaer A, (2008) VPS10P-domain receptors - regulators of neuronal viability and function. Nat Rev Neurosci 9: 899-909.
38. Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, et al. (2010) Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68: 654-667.
39. Kornfeld S, (1992) Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem 61: 307-330.
40. Oka Y, Rozek LM, Czech MP, (1985) Direct demonstration of rapid insulin-like growth factor II Receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. J Biol Chem 260: 9435-9442.
41. Quistgaard EM, Madsen P, Groftehauge MK, Nissen P, Petersen CM, et al. (2009) Ligands bind to Sortilin in the tunnel of a ten-bladed beta-propeller domain. Nat Struct Mol Biol 16: 96-98.
42. Lee K, Jin X, Zhang K, Copertino L, Andrews L, et al. (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13: 305-313.
43. Viemann D, Goebeler M, Schmid S, Nordhues U, Klimmek K, et al. (2006) TNF induces distinct gene expression programs in microvascular and macrovascular human endothelial cells. Journal of leukocyte biology 80: 174-185.
44. Aird WC, (2007) Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circulation research 100: 174-190.
45. Cleaver O, Melton DA, (2003) Endothelial signaling during development. Nat Med 9: 661-668.